The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope

Mercer, Louise; Abhishek, Abhishek; Kavirayani, Akhila; Ahmed, Alison; Davidson, Alan; Foulkes, Amy; Jones, Claire; Nash, Clare; Rose-Parfitt, Emily; Dhillon, Emmandeep; Zabate, Genevieve; Twohig, Helen; De Vere, Hope; Scott, Jennifer; Reynolds, John; Holmes, Julia; Hartley, Karen; Warrier, Kishore; Nowak, Kataryzna; Parsons, Kate; Bechman, Katie; Bray, Lisa; Adikari, Madura; Wood, Natasha; Faithfull, Nicola; Gullick, Nicola; Saha, Pratyasha; Heaton, Rebecca; Deepak, Samundeeswari; Hider, Samantha; Khalid, Sameena; Suleiman Said, Sanaa; Ryan, Sarah; Kyle, Stuart; Raghuvanshi, Subhra; Tan, Su-Yin; Shivamurthy, Vinay; Galloway, James

Abstract

Lay Summary: What does this mean for patients? A revised guideline, produced by the British Society for Rheumatology (BSR), will provide up-to-date information about the safe prescribing and monitoring of the effects of non-biologic (or conventional synthetic) disease-modifying anti-rheumatic drugs (DMARDs). This guideline will be used by healthcare professionals, people living with autoimmune rheumatic diseases and other interested parties, such as patient groups and charities. DMARDs are a group of drugs prescribed to people with autoimmune rheumatic diseases. The main aims of these drugs are to control symptoms and reduce or prevent long-term progression of the disease. Biologic drugs and Janus kinase inhibitors—sometimes referred to as biologic DMARDs and targeted synthetic DMARDs, respectively—are excluded from this guideline. This article outlines the scope of the revised guideline for DMARD safety, which will be updated to include new information and is being extended to include children and young people. Guideline revisions will be undertaken by a working group of adult and paediatric and adolescent rheumatologists, other healthcare professionals and people living with autoimmune rheumatic disease. The guideline will be developed using the methods and processes outlined in the BSR document ‘Creating clinical guidelines: our protocol’.

Citation

Mercer, L., Abhishek, A., Kavirayani, A., Ahmed, A., Davidson, A., Foulkes, A., …Galloway, J. (in press). The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope. Rheumatology Advances in Practice, 8(3), Article rkae077. https://doi.org/10.1093/rap/rkae077

• Journal Article Type: Article
• Acceptance Date: May 22, 2024
• Online Publication Date: Jul 12, 2024
• Deposit Date: Jul 15, 2024
• Publicly Available Date: Jul 15, 2024
• Journal: Rheumatology Advances in Practice
• Print ISSN: 2514-1775
• Electronic ISSN: 2514-1775
• Publisher: Oxford University Press
• Peer Reviewed: Peer Reviewed
• Volume: 8
• Issue: 3
• Article Number: rkae077
• DOI: https://doi.org/10.1093/rap/rkae077
• Keywords: DMARD management guideline
• Public URL: https://keele-repository.worktribe.com/output/875438